经过12个月的治疗，结果显示，通心络组纤维帽厚度平均增幅为61.2微米，对照组为33.7微米，前者几 乎为后者的两倍，而且通心络这一作用具有较好的普适性，在不同年龄、性别、有无2型糖尿病、不同 冠脉病变类型等亚组中表现一致；同时，通心络组冠状动脉斑块最大脂质弧度平均降幅（约-38°）也显 著大于对照组（约-8°）。简单来讲，增加斑块纤维帽厚度、减少脂质弧度，就预示着斑块更稳定，更 不容易破裂，就像厚皮小馅的饺子相较薄皮大馅的更不容易破裂一样。这些结果共同表明，在现代他汀 等标准治疗的基础上，联合通心络能进一步增加易损斑块纤维帽厚度、减少脂质成分，朝着"更稳定"的 方向重塑斑块结构。此外，该研究还发现，与对照组相比，通心络组患者心绞痛症状得到明显改善，且 安全性良好。 该研究首次采用国际评价易损斑块的"金标准"——光学相干断层成像技术，以高分辨率冠脉OCT影像学 为切入点，首次在急性冠状动脉综合征患者中提供了通心络稳定冠状动脉易损斑块的高质量影像学证 据，并为通心络降低急性冠脉综合征残余心血管风险的潜在机制提供了有力支持，为心血管事件链干预 环节中稳定易损斑块减少心血管事件提供了有效药物，处于国际并跑水平。 2 ...

DXS INTERNATIONAL PLC (AQSE: DXSP) HALF YEAR RESULTS DXS International plc ("DXS" or the "Company"), the digital clinical decision support company, is pleased to provide shareholders with its unaudited interim results for the half year ending 31 October 2025. H1 2025 Financial highlights: Core recurring revenue model remains resilient. Revenue decreased by 2.6% to £1,684,712 (H1 2024 - £1,730,829) in the six months to 31 October 2025 ("Period"). Administration costs decreased by 5% in the Period (H1 2024 - ...

Core Insights - Novo Nordisk's semaglutide injection (brand name: Ozempic) has received approval from the National Medical Products Administration (NMPA) in China for cardiovascular indications, aimed at reducing the risk of major cardiovascular adverse events in adults with cardiovascular disease and a BMI ≥ 27 kg/m² [1][2] Group 1: Product Approval and Efficacy - The approval is based on the SELECT trial, which is the largest cardiovascular outcomes trial completed for patients with obesity and cardiovascular disease, involving 17,604 participants [4] - The SELECT trial results indicated that semaglutide injection reduced the risk of major adverse cardiovascular events (MACE) by 20%, cardiovascular death by 15%, heart failure composite endpoint by 18%, and all-cause mortality by 19% compared to placebo [4] - Early treatment with semaglutide showed protective effects on the heart before significant weight loss occurred, suggesting benefits in reducing MACE risk regardless of weight reduction [4] Group 2: Market Context and Health Implications - Approximately 4 million people die from cardiovascular diseases in China each year, accounting for over 40% of total deaths, with obesity being a significant independent risk factor for cardiovascular morbidity and mortality [3] - The treatment guidelines in both Europe and China emphasize the importance of weight management in overweight/obese patients to lower cardiovascular risks, with semaglutide being the only drug recommended for this purpose [3][4] - Real-world studies, such as the STEER study, demonstrated that patients treated with semaglutide had a 57% lower risk of heart attack, stroke, and all-cause mortality compared to those treated with tirzepatide, reinforcing the unique cardiovascular benefits of semaglutide [5] Group 3: Company Strategy and Future Outlook - Novo Nordisk aims to transform obesity treatment concepts and improve cardiovascular outcomes for overweight and obese patients through the broader clinical application of semaglutide [5] - The company is committed to addressing diverse needs in obesity treatment and continues to innovate in its research pipeline to combat obesity stigma and promote effective prevention strategies [5]

Core Insights - The Ninth Hu-Lu Cardiovascular Disease Expert Forum and several other significant academic meetings were held in Rizhao, focusing on advancements in cardiovascular disease treatment and collaboration among experts in the field [1][5][9]. Group 1: Event Overview - The event included multiple important academic activities such as the Hu-Lu Cardiovascular Disease Expert Forum, the 21st CTOCC meeting, and the first session of the CCI Innovation Academy, aimed at integrating high-quality resources and enhancing efficiency in cardiovascular medicine [9][10]. - The forum has evolved over nine years into a prestigious academic event, emphasizing the core values of inheritance, innovation, cooperation, and talent cultivation in the medical field [5][7]. Group 2: Expert Contributions - Key experts, including Professor Ge Junbo and Professor Huo Yong, highlighted the importance of multi-conference collaboration in advancing cardiovascular medicine and fostering regional cooperation [7][9]. - The event showcased successful demonstrations of complex chronic total occlusion (CTO) surgeries, emphasizing the application of innovative techniques and the sharing of clinical experiences among top experts [12][14]. Group 3: Institutional Achievements - The Qingdao University Affiliated Rizhao Hospital has completed over 20,000 surgeries in seven years, establishing itself as a trusted institution in the region and achieving significant technical breakthroughs [9][16]. - The hospital has introduced numerous new techniques, including several firsts in Shandong province, reinforcing its commitment to advancing cardiovascular care and ensuring public health [16].

Group 1 - Novo Nordisk has entered the Indian market with its weight loss drug Wegovy, which has been approved for long-term chronic weight management and reducing the risk of major cardiovascular events [1][2] - Wegovy will be available in five dosages, with the starting dose of 0.25 mg priced at 4,336.25 INR (approximately 50.3 USD) and the highest dose of 2.4 mg priced at 6,503.75 INR, significantly lower than its US price of 337.25 USD [1] - The introduction of Wegovy follows a recommendation from the American College of Cardiology to use semaglutide as a first-line treatment for cardiovascular diseases, addressing a significant health issue in India where heart disease is a leading cause of death [2] Group 2 - Novo Nordisk aims to collaborate with insurance companies and financial institutions to enhance the affordability and accessibility of Wegovy, and is considering partnerships with local companies for further product promotion [3] - The market for weight loss therapies in India is growing, as evidenced by a 60% month-on-month increase in sales of Eli Lilly's Mounjaro since its launch, indicating strong consumer interest in such treatments [3] - Novo Nordisk plans to introduce its next-generation anti-obesity candidates, CagriSema and amycretin, which are currently in clinical trials, and is preparing for the market after the expiration of the semaglutide patent in Q2 2026 [3]

Core Insights - Jiangsu Hengrui Medicine Co., Ltd. has signed a collaboration agreement with Merck to license its oral small molecule drug targeting lipoprotein(a) (HRS-5346) for a payment of $200 million upfront [3][4] - The agreement allows Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 outside Greater China, with potential milestone payments reaching up to $1.77 billion and additional sales royalties based on performance [3][4] - HRS-5346 is currently undergoing Phase II clinical trials in China and targets elevated Lp(a) levels, which are linked to cardiovascular diseases [4][5] Financial Implications - The total potential revenue for Hengrui from this collaboration could approach $2 billion, including upfront payments, milestone payments, and sales royalties [3][4] - Hengrui has previously engaged in 12 licensing deals since 2018, totaling approximately $12 billion, with upfront payments around $400 million [4] Strategic Importance - This partnership is expected to enhance Hengrui's international market presence and improve its innovative brand and overseas performance [5] - The collaboration aligns with Hengrui's strategy of balancing in-house development with external partnerships to accelerate the global reach of its innovative products [5]